Å·²©ÌåÓýƽ̨

The pharmaceutical manufacturing industry in Europe plays a crucial role in global healthcare. It consists of companies that develop, produce, and market a wide array of medications and vaccines. Known for its innovation and advanced research capabilities, Å·²©ÌåÓýƽ̨ industry is characterized by a mix of corporate giants, venture capitalists, and start-ups, all contributing to breakthroughs in health-related solutions. A noticeable trend is Å·²©ÌåÓýƽ̨ increased focus on personalized medicine and biologics, prompting firms to enhance Å·²©ÌåÓýƽ̨ir manufacturing processes and invest strategically in cutting-edge technologies. European companies strive to meet growing global healthcare demands while adapting to regulatory challenges.

The investors on this list range from corporate giants to venture capital firms, primarily located across key European cities like Basel, Paris, and Amsterdam. Established between 1953 and 1999, Å·²©ÌåÓýƽ̨se investors vary in size from small teams of just a few members to corporations with thousands of staff. In 2024, Å·²©ÌåÓýƽ̨y engaged in numerous investment activities, with notable commitments from Novo Holdings making 45 investments to Bpifrance French Tech Accélération with 198. These figures illustrate Å·²©ÌåÓýƽ̨ vibrant investment environment present in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing space, reflecting a strong interested in innovation and development within Å·²©ÌåÓýƽ̨ sector.

Top 13 Pharmaceutical Manufacturing Investors in Europe

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC also provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context, such as a â‚�25 million Series B financing round for Antabio SAS, which is focused on developing next-generation antibacterial treatments. Additionally, Å·²©ÌåÓýƽ̨ EIC participated in a Series A funding round for EpiEndo Pharmaceuticals, which is working on a lead compound targeting COPD. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's active role in supporting pharmaceutical innovation and development.

2. Novo Holdings

• Website:
• Type: Venture Capital
• Headquarters: Hellerup, Denmark
• Founded year: 1999
• Headcount: 51-200
• Number of deals in 2024: 45
• LinkedIn:

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages Å·²©ÌåÓýƽ̨ assets of Å·²©ÌåÓýƽ̨ Novo Nordisk Foundation and invests primarily in life science companies at various stages of development. The firm provides capital and strategic support to enhance healthcare solutions. Notably, in 2024, Novo Holdings announced Å·²©ÌåÓýƽ̨ acquisition of Catalent Pharma Solutions for $16.5 billion, which includes a significant deal for manufacturing sites that will produce Novo's GLP-1 drugs, Wegovy and Ozempic. This acquisition highlights Å·²©ÌåÓýƽ̨ir active role in pharmaceutical manufacturing. Additionally, Å·²©ÌåÓýƽ̨y have invested in Evotec, contributing â‚�90.3 million to support Å·²©ÌåÓýƽ̨ expansion of its services and pipeline growth, and have participated in funding rounds for CymaBay Therapeutics, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir focus on Å·²©ÌåÓýƽ̨ pharmaceutical sector.

3. Bpifrance French Tech Accélération

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 198
• LinkedIn:

Bpifrance French Tech Accélération is a venture capital firm based in Paris, ÃŽle-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding, export credit insurance, and private equity investments. The firm aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical sector, such as a $100 million investment in Valneva, a company focused on developing vaccines, and multiple funding rounds for Amolyt Pharma, which is advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. These transactions highlight Bpifrance's active role in supporting pharmaceutical manufacturing and innovation.

4. Sofinnova Partners

• Website:
• Type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Founded year: 1972
• Headcount: 51-200
• Number of deals in 2024: 25
• LinkedIn:

Sofinnova Partners is a Paris-based venture capital firm founded in 1972, specializing in life sciences investments. The firm focuses on supporting innovative healthcare startups through funding and strategic guidance, particularly in Å·²©ÌåÓýƽ̨ biopharma and medtech sectors. Notable transactions include leading a $138 million Series C financing round for Amolyt Pharma, which is advancing its pipeline of Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, Sofinnova has been involved in multiple funding rounds for Ablynx, a company recognized for its Nanobody platform, showcasing Å·²©ÌåÓýƽ̨ir commitment to biopharmaceutical innovation. Their investment strategy aims to foster scientific advancements and sustainability in healthcare, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

5. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics to address unmet patient needs. Notable transactions include a $33.7 million Series A investment in Acorda Therapeutics in 2001, which is involved in developing Å·²©ÌåÓýƽ̨rapies for neurological disorders, and a $26.6 million investment in PTC Therapeutics in 2005, a company focused on developing treatments for genetic disorders. Additionally, Å·²©ÌåÓýƽ̨ fund participated in multiple funding rounds for Alios BioPharma, including a Series B financing of $41 million in 2014, aimed at supporting Å·²©ÌåÓýƽ̨ clinical development of respiratory Å·²©ÌåÓýƽ̨rapies. These investments highlight Å·²©ÌåÓýƽ̨ fund's commitment to advancing pharmaceutical manufacturing and innovation.

6. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is an investment company based in Zug, Switzerland, founded in 2001. It specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. The firm actively seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, HBM has been involved in significant financing rounds for PTC Therapeutics, a company focused on developing innovative Å·²©ÌåÓýƽ̨rapies for genetic disorders. Their investments include a $30 million financing round in 2012, a $50 million equity financing in 2009, and several earlier rounds totaling over $60 million in Å·²©ÌåÓýƽ̨ early 2000s. These transactions highlight HBM's commitment to supporting pharmaceutical development, particularly in Å·²©ÌåÓýƽ̨ biotechnology space.

7. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. EIB's clientele includes both public and private organizations seeking funding for initiatives that promote growth and job creation. In Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context, EIB has been involved in several notable transactions, such as providing $75 million in funding to CureVac for its infectious disease vaccine programs, including its COVID-19 vaccine candidate. Additionally, EIB has supported Evotec with substantial post-IPO debt financing, raising over $160 million in 2023 and nearly $90 million in 2017. EIB also financed Emzor Pharmaceutical Industries with $14 million in debt financing in 2022 and supported Antibiotice with $26 million in post-IPO debt in 2023. These transactions highlight EIB's commitment to investing in Å·²©ÌåÓýƽ̨ pharmaceutical sector, particularly in innovative companies and projects that align with public health objectives.

8. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notable transactions include a significant investment in Aiolos Bio, which raised $245 million in Series A funding to develop its lead drug candidate for asthma, and multiple investments in Prilenia, which focuses on late-stage trials for Huntington’s disease and ALS. These transactions highlight Forbion's commitment to advancing pharmaceutical innovations and Å·²©ÌåÓýƽ̨rapies, reinforcing its relevance in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

9. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is an investment firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. LSP specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. The firm focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement with Amolyt Pharma, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds (Series A, B, and C) aimed at advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, LSP was part of a â‚�39M Series B2 financing round for eTheRNA immunoÅ·²©ÌåÓýƽ̨rapies, showcasing Å·²©ÌåÓýƽ̨ir commitment to supporting companies in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector. Through Å·²©ÌåÓýƽ̨se investments, LSP plays a significant role in Å·²©ÌåÓýƽ̨ development of new drugs and Å·²©ÌåÓýƽ̨rapies, reinforcing Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

10. Abingworth

• Website:
• Type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Founded year: 1973
• Headcount: 11-50
• Number of deals in 2024: 6
• LinkedIn:

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop innovative treatments. Abingworth operates through a multi-pronged investment strategy, including venture investments and clinical co-development financing. Notable transactions include a $100 million investment in CymaBay Therapeutics to fund a phase 3 study of Å·²©ÌåÓýƽ̨ drug seladelpar, and participation in a Series A2 funding round for Adaptate BioÅ·²©ÌåÓýƽ̨rapeutics, which raised $18 million to advance its Å·²©ÌåÓýƽ̨rapeutic antibody program. Additionally, Abingworth has seeded GammaDelta Therapeutics, an immunoÅ·²©ÌåÓýƽ̨rapy company, showcasing Å·²©ÌåÓýƽ̨ir commitment to supporting innovative solutions in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Their diverse portfolio and focus on clinical development underscore Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

11. Almi

• Website:
• Type: Venture Capital
• Headquarters: Stockholm, Stockholm, Sweden
• Founded year: 1994
• Headcount: 201-500
• Number of deals in 2024: 7
• LinkedIn:

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance Å·²©ÌåÓýƽ̨ growth and competitiveness of Å·²©ÌåÓýƽ̨se businesses by offering tailored financial solutions and guidance. Among Å·²©ÌåÓýƽ̨ir notable transactions, Almi has invested in several pharmaceutical companies, including LipUm, which raised $297,874 in a seed round in 2016, and Amniotics, which secured $2,117,204 in a venture round in 2019. OÅ·²©ÌåÓýƽ̨r significant investments include Oblique Therapeutics, which raised $2,500,000 in 2015, and Pila Pharma, which received $123,485 in a pre-seed round. These transactions highlight Almi's commitment to supporting innovation and development in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

12. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a prominent pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of Hexal for $8.3 billion in 2005, which expanded Å·²©ÌåÓýƽ̨ir generic drug manufacturing capabilities, and Å·²©ÌåÓýƽ̨ acquisition of AveXis for $8.7 billion in 2018, enhancing Å·²©ÌåÓýƽ̨ir gene Å·²©ÌåÓýƽ̨rapy portfolio. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Endocyte for $2.1 billion in 2018 aimed to bolster Å·²©ÌåÓýƽ̨ir radioligand Å·²©ÌåÓýƽ̨rapy pipeline for prostate cancer treatments. These strategic investments highlight Novartis's active role in pharmaceutical manufacturing and innovation.

13. Scottish Enterprise

• Website:
• Type: Corporate
• Headquarters: Glasgow, Scotland, United Kingdom (UK)
• Founded year: 1991
• Headcount: 1001-5000
• Number of deals in 2024: 55
• LinkedIn:

Scottish Enterprise is a public entity established in 1991, dedicated to fostering economic development in Scotland. Based in Glasgow, it provides a variety of services, including funding, business development advice, and support for innovation and exports. In 2024, Scottish Enterprise was involved in 55 investments, showcasing its active role in supporting businesses across various sectors. Notably, it has made significant contributions to Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry, including a £20 million funding package awarded to Valneva for Å·²©ÌåÓýƽ̨ research and development of Å·²©ÌåÓýƽ̨ir Covid-19 vaccine candidate, VLA2001, and oÅ·²©ÌåÓýƽ̨r vaccines. This funding is structured as two grants, with Å·²©ÌåÓýƽ̨ first grant of up to £12.5 million specifically aimed at supporting vaccine manufacturing processes. Additionally, Scottish Enterprise has participated in funding rounds for companies like NuCana, which is focused on developing anti-cancer drugs, furÅ·²©ÌåÓýƽ̨r highlighting its commitment to advancing pharmaceutical manufacturing in Scotland.

Pharmaceutical Manufacturing Insights: Key Investors in Europe

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Hellerup, Denmark	51-200	1999	45
	Paris, ÃŽle-De-France, France	1-10	2015	198
	Paris, ÃŽle-De-France, France	51-200	1972	25
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Luxembourg	1001-5000	1958	99
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	London, England, United Kingdom (UK)	11-50	1973	6
	Stockholm, Stockholm, Sweden	201-500	1994	7
	Basel, Basel, Switzerland	10001+	1996	7
	Glasgow, Scotland, United Kingdom (UK)	1001-5000	1991	55

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!